| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7e2f8fb5650d7d3616661464b67771 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-05-24^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ea20456123adbd54b1552310705b9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b168e38b88091a08a8ef06e5c5d8ff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeb1bef21626a7e7a93fbbf86de0b253
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df22ce6b3c32c16c5339ebb5c1a22c6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57e8d63238fe2b37ddbc9702ccda9bdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0144fcf8246f3342d97fca745641af19 |
| publicationDate |
2021-05-05^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3816166-A1 |
| titleOfInvention |
Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer |
| abstract |
The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer. |
| priorityDate |
2018-05-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |